Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Enlicitide in Participants With Hepatic Impairment
NCT06575959Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of enlicitide in hypercholesterolemia (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration Versus Time Curve From Time 0 to Infinity at 168 hours and Maximum Concentration at 168 hours. Started Sep 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06575959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575959.